1. Generics Bulletin
  2. >>Products

What’s Next? Five Things To Look Out For In January

Viatris Gains Key Advantage For Interchangeable Insulin Biosimilar

 
• By Dean Rudge

Sun Pharma’s key antitrust trial kicks off and Lannett awaits word from the US FDA for its generic Advair filing during a busy first month of 2022, which also features updates from the annual J.P. Morgan Health Care Conference.

What's Next Image
All the significant events coming up in January 2022 • Source: Informa

This month, Viatris is to realize a significant commercial boost for its interchangeable biosimilar Semglee (insulin glargine-yfgn) in the US, with the product having moved to preferred status on pharmacy benefit manager Express Scripts’ largest national formulary from 1 January 2022. (Also see "Viatris’ Interchangeable Semglee Lands On Express Scripts Formulary" - Generics Bulletin, 22 October, 2021.)

Prime Therapeutics, a PBM which serves nearly 33 million people and is collectively owned by 19 Blue Cross and Blue...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Generics Bulletin’s Top 50 Ranking For 2025

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

The Generics Bulletin Top 50, Part Three: New Firms Enter Global Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.

Latest EMA Biosimilar Nods Come For Henlius, Alteogen And Biocon

 
• By Dave Wallace

Denosumab, aflibercept and ustekinumab biosimilars received positive opinions from the EMA’s CHMP at its meeting in July, along with an Opsumit generic from Accord.